logo
Teaching blood cells how to 'switch off' arthritis

Teaching blood cells how to 'switch off' arthritis

Yahoo24-03-2025

Patients are taking part in a trial that scientists hope could ultimately lead to a cure for rheumatoid arthritis.
The AuToDeCRA-2 study seeks to prove it is possible to train white blood cell commanders - dubbed the "generals" of the immune system - to order other "soldier" cells to stop attacking healthy tissues.
Prof John Isaacs, who has worked on the condition for 35 years and is leading the research, believes this could make it possible to "switch off" rheumatoid arthritis.
Trial participant Carol Robson, from Jarrow in South Tyneside, says the worst part of living with the disease is the pain, but if the research helps ease suffering "that would be wonderful".
The study, funded by the charity Versus Arthritis and the European Commission, is being run by Newcastle University and Newcastle Hospitals.
"It's pioneering," Prof Isaacs claims. "There are only one or two other groups around the world doing similar work."
In this latest research, now in its second phase, certain cells are isolated from a patient's blood.
Prof Isaacs explained there are different types of cells that come together, rather like an army of soldiers, to attack an infection or disease.
These take instructions from the white blood cells known as dendritic cells, which he refers to as the "generals" of the immune system.
When these generals sense danger they become excited and send out the attack signal, but when there is no danger detected they remain calm and instruct the army to ignore healthy tissues.
When this goes wrong it causes diseases like rheumatoid arthritis.
Over the course of a week the patient's white blood cells are grown in the lab and trained to resemble the "calm" generals so that, when given back to the patient, they command the soldiers to stop attacking the patient's joints.
"In time, this treatment could provide significant benefits to people living with rheumatoid arthritis by 'switching off' the disease," Prof Isaacs explains.
Among the estimated 450,000 people in England who live with the condition is 70-year-old former nurse Ms Robson. She wakes up every morning to pain.
Before she was diagnosed she would put her hands in packets of frozen peas in an effort to find some relief.
She now takes immunosuppressants, which she says help a bit, but since being injected with the retrained white blood cells she believes she is in less pain.
"Is this just me hoping it is? But realistically I do think it is better," she says.
"If this trial works to switch off rheumatoid arthritis that would be wonderful.
"It's a privilege to be part of something that is actually quite a leap forward - if they get it right."
The outcome of the Newcastle work is being widely monitored as it could have huge implications for the 18 million rheumatoid arthritis patients worldwide.
Prof Isaacs said, if its successful, the research could also have implications for other autoimmune diseases such as diabetes or multiple sclerosis.
"It's an area of research that we describe as re-education of the immune system.
The first two trials are small - in total about 32 patients have been involved - and more research is needed, but if it shows signs of success another, larger trial will follow.
Even if all goes to plan and the treatment is shown to re-educate the immune system, it may still be another five to 10 years before patients are able to access it.
But Prof Isaacs, who has dedicated his career to the condition, said it would make him and his team immensely proud to have developed the treatment.
Follow BBC North East on X, Facebook, Nextdoor and Instagram.
AI researchers work on detecting arthritis earlier
Newcastle Hospitals
Professor John Isaacs
Versus Arthritis

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress

Yahoo

time2 hours ago

  • Yahoo

Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress

ROCKVILLE, Md. and SUZHOU, China, June 09, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that 13 studies of its core assets - including the novel drug olverembatinib (HQP1351), the investigational Bcl-2 inhibitor lisaftoclax (APG-2575), and the investigational EED inhibitor APG-5918 – will be featured in an oral presentation, multiple poster presentations and multiple online publications at the 2025 European Hematology Association (EHA) Annual Congress taking place in Milan, Italy, from June 12-15, 2025. The EHA Annual Congress is the largest gathering of the hematology community in Europe. Attracting more than 10,000 attendees from more than 100 countries every year, the congress showcases cutting-edge research and ground-breaking clinical results in the field of hematology. Oral PresentationIntegrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy Abstract#: S162 Session: Biology of CML treatment response and resistance Date and Time: Saturday, 14 June, 17:30-17:45 CEST / Saturday, 14 June, 23:30-23:45 Beijing Time Principal Authors: Prof. Qian Jiang, Peking University People's Hospital; Dr. Xiaoshuai Zhang, Peking University People's Hospital Poster PresentationsFrontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study Abstract#: PF384 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time Principal Author: Prof. Xiaowen Tang, The First Affiliated Hospital of Soochow University; Xin Zhang, The First Affiliated Hospital of Soochow University A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Abstract#: PF390 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Suning Chen, The First Affiliated Hospital of Soochow University; Wenzhi Cai, The First Affiliated Hospital of Soochow University Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia Abstract#: PS1367 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Hongsheng Zhou, Nanfang Hospital, Southern Medical University; Xiuli Xu, Nanfang Hospital, Southern Medical University Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial Abstract#: PS1372 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Authors: Prof. Jie Jin, The First Affiliated Hospital, Zhejiang University School of Medicine; Dr. Gaixiang Xu, The First Affiliated Hospital, Zhejiang University School of Medicine Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study Abstract#: PS1387 Session: Acute lymphoblastic leukemia – Clinical Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time Principal Author: Erlie Jiang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Xiaoyu Zhang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models Abstract#: PS1993 Session: Lymphoma biology & translational research Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Principal Author: Dr. Eric Liang, Ascentage Pharma Group Inc. Online PublicationsAlternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis Abstract: PB2384 Principal Author: Prof. Zi-Yuan Nie, The Second Hospital of Hebei Medical University Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive/Negative B-Cell Acute Lymphoblastic Leukemia Abstract#: PB2363 Principal Author: Yinqiang Zhang, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Abstract#: PB2360 Principal Author: Xinwen Jiang, The Second Hospital of Hebei Medical University Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study Abstract#: PB2701 Principal Author: Mengyao Yuan, Peking University People's Hospital A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study Abstract#: PB2714 Principal Author: Tian Dong, West China Hospital of Sichuan University Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL) Abstract#: PB2341 Principal Author: Bo Peng, Ascentage Pharma (Suzhou) Co., Ltd. About Ascentage PharmaAscentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph+ ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML, and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma +86 512 85557777 Stephanie Carrington ICR Healthcare +1 (646) 277-1282 Media Relations: Sean Leous ICR Healthcare +1 (646) 866-4012Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Private astronaut mission marks next step toward a new space station
Private astronaut mission marks next step toward a new space station

Yahoo

time4 hours ago

  • Yahoo

Private astronaut mission marks next step toward a new space station

NASA is planning on decommissioning the International Space Station (ISS) by the end of 2030. But before that happens, Axiom Space, a privately funded space infrastructure company based in Houston, wants to build a replacement. The company has begun construction of the world's first commercial space station, Axiom Station. But Axiom isn't waiting for their station to be completed before transporting people into space. The company has been launching teams of private astronauts to the ISS since 2022, allowing them to conduct research, train, and participate in scientific activities. And on Wednesday at 8 a.m., Axiom Space will attempt to send its fourth crew to the ISS as part of its AX-4 mission. "The AX-4 crew represents the very best of international collaboration, dedication, and human potential. Over the past 10 months, these astronauts have trained with focus and determination, each of them exceeding the required thresholds to ensure mission safety, scientific rigor and operational excellence," said Allen Flynt, Axiom Space's chief of mission services, during a pre-launch press conference on Monday. The four-person crew will lift off from Launch Complex 39A at NASA's Kennedy Space Center in Florida and travel to the ISS aboard a SpaceX Dragon spacecraft launched into orbit by a Falcon 9 rocket. It will be the maiden mission for an updated Dragon capsule. MORE: A private company wants to build a city on the moon. But it has to land a probe first "This is the first flight for this Dragon capsule, and it's carrying an international crew—a perfect debut. We've upgraded storage, propulsion components and the seat lash design for improved reliability and reuse," said William Gerstenmaier, SpaceX's vice president of build and flight reliability. The mission will be led by Peggy Whitson, a former NASA astronaut and the director of human spaceflight at Axiom. During her career at NASA, Whitson completed three long-duration space flights, spending a total of 665 days in orbit. She also commanded Axiom's AX-2 mission, adding another 10 days in space to her already impressive total. Whitson now holds the record for the most time spent in space by a woman. "We're thrilled to welcome Peggy Whitson back. This will be her fifth trip to space—three with NASA and now two with Axiom," Dana Weigel, NASA's manager of the International Space Station Program, said. "She's made substantial contributions to ISS and now helps lay the foundation for future commercial missions." Joining Whitson on the AX-4 mission are astronauts from India, Poland and Hungary. This will be the first time that nationally sponsored astronauts from those countries have visited the ISS. It has also been more than 40 years since those three countries sent someone into space. MORE: New Biomass satellite will provide an unprecedented look at the planet's forests Indian Air Force pilot and astronaut Shubhanshu Shukla, the mission's pilot, will be the second person from India to go to space and the first since 1984. Polish engineer Sławosz Uznański, a mission specialist and a European Space Agency project astronaut, will be the second person from his country to head to space and the first since 1978. And Tibor Kapu, a mechanical engineer and mission specialist, will be the second Hungarian astronaut to rocket into space. That country's last space mission was 45 years ago. "For India, Poland, and Hungary, this mission marks a return to human spaceflight after more than 40 years, and their first missions to the ISS. It's a powerful reminder of what we can achieve when we work together across borders, disciplines, and cultures," Flynt said. The AX-4 mission will last up to 14 days, during which the crew will conduct about 60 scientific studies and experiments. The company said 31 countries have contributed to the research plan and that the projects will focus on biological, life and material sciences, as well as Earth observation. Axiom said that the work done at the station will help the company advance its goal of building Axiom Station, which would be the world's first commercial space station. To lay the foundation for its space station, Axiom plans to attach several of its commercial modules to the ISS while it's still operational. When the ISS is decommissioned, those modules will detach from the station and become part of the privately run Axiom Station. Unlike space tourism, which is operated independently of NASA and government support, the Axiom mission is part of NASA's private astronaut mission program. This private-public partnership provides selected commercial space companies with access to the ISS and technical and logistical support from NASA. "NASA's framework for private astronaut missions gives industry responsibility for launch, free flight, and landing," Weigel said. "It's an incredible time for spaceflight. These missions help train teams, build partnerships and shape the future of low Earth orbit," she added.

Private astronaut mission marks next step toward a new space station

time4 hours ago

Private astronaut mission marks next step toward a new space station

NASA is planning on decommissioning the International Space Station (ISS) by the end of 2030. But before that happens, Axiom Space, a privately funded space infrastructure company based in Houston, wants to build a replacement. The company has begun construction of the world's first commercial space station, Axiom Station. But Axiom isn't waiting for their station to be completed before transporting people into space. The company has been launching teams of private astronauts to the ISS since 2022, allowing them to conduct research, train, and participate in scientific activities. And on Wednesday at 8 a.m., Axiom Space will attempt to send its fourth crew to the ISS as part of its AX-4 mission. "The AX-4 crew represents the very best of international collaboration, dedication, and human potential. Over the past 10 months, these astronauts have trained with focus and determination, each of them exceeding the required thresholds to ensure mission safety, scientific rigor and operational excellence," said Allen Flynt, Axiom Space's chief of mission services, during a pre-launch press conference on Monday. The four-person crew will lift off from Launch Complex 39A at NASA's Kennedy Space Center in Florida and travel to the ISS aboard a SpaceX Dragon spacecraft launched into orbit by a Falcon 9 rocket. It will be the maiden mission for an updated Dragon capsule. "This is the first flight for this Dragon capsule, and it's carrying an international crew—a perfect debut. We've upgraded storage, propulsion components and the seat lash design for improved reliability and reuse," said William Gerstenmaier, SpaceX's vice president of build and flight reliability. The mission will be led by Peggy Whitson, a former NASA astronaut and the director of human spaceflight at Axiom. During her career at NASA, Whitson completed three long-duration space flights, spending a total of 665 days in orbit. She also commanded Axiom's AX-2 mission, adding another 10 days in space to her already impressive total. Whitson now holds the record for the most time spent in space by a woman. "We're thrilled to welcome Peggy Whitson back. This will be her fifth trip to space—three with NASA and now two with Axiom," Dana Weigel, NASA's manager of the International Space Station Program, said. "She's made substantial contributions to ISS and now helps lay the foundation for future commercial missions." Joining Whitson on the AX-4 mission are astronauts from India, Poland and Hungary. This will be the first time that nationally sponsored astronauts from those countries have visited the ISS. It has also been more than 40 years since those three countries sent someone into space. Indian Air Force pilot and astronaut Shubhanshu Shukla, the mission's pilot, will be the second person from India to go to space and the first since 1984. Polish engineer Sławosz Uznański, a mission specialist and a European Space Agency project astronaut, will be the second person from his country to head to space and the first since 1978. And Tibor Kapu, a mechanical engineer and mission specialist, will be the second Hungarian astronaut to rocket into space. That country's last space mission was 45 years ago. "For India, Poland, and Hungary, this mission marks a return to human spaceflight after more than 40 years, and their first missions to the ISS. It's a powerful reminder of what we can achieve when we work together across borders, disciplines, and cultures," Flynt said. The AX-4 mission will last up to 14 days, during which the crew will conduct about 60 scientific studies and experiments. The company said 31 countries have contributed to the research plan and that the projects will focus on biological, life and material sciences, as well as Earth observation. Axiom said that the work done at the station will help the company advance its goal of building Axiom Station, which would be the world's first commercial space station. To lay the foundation for its space station, Axiom plans to attach several of its commercial modules to the ISS while it's still operational. When the ISS is decommissioned, those modules will detach from the station and become part of the privately run Axiom Station. Unlike space tourism, which is operated independently of NASA and government support, the Axiom mission is part of NASA's private astronaut mission program. This private-public partnership provides selected commercial space companies with access to the ISS and technical and logistical support from NASA. "NASA's framework for private astronaut missions gives industry responsibility for launch, free flight, and landing," Weigel said. "It's an incredible time for spaceflight. These missions help train teams, build partnerships and shape the future of low Earth orbit," she added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store